Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: What is the evidence?

Metabolic Brain Disease

Volumn 28, Issue 2, 2013, Pages 221-225

  Gluud, Lise Lotte ^a   Dam, Gitte ^b   Borre, Mette ^b   Les, Iñigo ^c   Cordoba, Juan ^c   Marchesini, Giulio ^d   Aagaard, Niels Kristian ^b   Vilstrup, Hendrik ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cirrhosis; Meta analysis; Randomized controlled trials; Systematic Review

Indexed keywords

ANTIBIOTIC AGENT; BRANCHED CHAIN AMINO ACID; LACTITOL; LACTULOSE; PLACEBO; RIFAXIMIN; ANTIINFECTIVE AGENT; DISACCHARIDE; GASTROINTESTINAL AGENT; RIFAMYCIN;

ANTIBIOTIC THERAPY; BLOATING; CONFERENCE PAPER; DIARRHEA; DRUG EFFECT; EVIDENCE BASED MEDICINE; HEPATIC ENCEPHALOPATHY; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SIDE EFFECT; SODIUM BLOOD LEVEL; SUPPLEMENTATION; SYSTEMATIC REVIEW (TOPIC); METABOLISM;

AMINO ACIDS, BRANCHED-CHAIN; ANTI-BACTERIAL AGENTS; DISACCHARIDES; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; LACTULOSE; RIFAMYCINS;

EID: 84878018203     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-012-9372-0     Document Type: Conference Paper

References (26)

1. Agrawal A, Sharma BC, Sharma P, Sarin SK (2012) Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 107(7):1043-1050
2. Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C (2003) Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev (2): CD001939
3. Als-Nielsen B, Gluud LL, Gluud C (2004) Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 328(7447):1046
4. Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ (2011) Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 140(2):478-487 e471
5. Bajaj JS, Wade JB, Gibson DP, Heuman DM, Thacker LR, Sterling RK, Stravitz RT, Luketic V, Fuchs M, White MB, Bell DE, Gilles H, Morton K, Noble N, Puri P, Sanyal AJ (2011b) The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol 106(9):1646-1653
6. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362(12):1071-1081
7. Bianchi G, Giovagnoli M, Sasdelli AS, Marchesini G (2012) Hepatic encephalopathy and health-related quality of life. Clin Liver Dis 16(1):159-170
8. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL (1977) Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 72(4 Pt 1):573-583
9. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT (2002) Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35(3):716-721
10. Germain L, Frexinos J, Louis A, Ribet A (1973) Double blind study of lactulose in 18 patients with chronic hepatic encephalopathy after portocaval shunt. Archives Francaises des Maladies de L'appareil Digestif 62(4):293-302
11. Jones EA (2002) Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy. Metab Brain Dis 17(4):275-281
12. Jones EA, Mullen KD (2012) Theories of the pathogenesis of hepatic encephalopathy. Clin Liver Dis 16(1):7-26
13. Les I, Doval E, Garcia-Martinez R, Planas M, Cardenas G, Gomez P, Flavia M, Jacas C, Minguez B, Vergara M, Soriano G, Vila C, Esteban R, Cordoba J (2011) Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol 106(6):1081-1088
14. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, Rossi Fanelli F, Abbiati R (2003) Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 124(7):1792-1801
15. Mittal VV, Sharma BC, Sharma P, Sarin SK (2011) A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 23(8):725-732
16. Morgan MY, Hawley KE (1987) Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 7(6):1278-1284
17. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H (2005) Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 3(7):705-713
18. Poordad FF (2007) Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 25(Suppl 1):3-9
19. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007) Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45(3):549-559
20. Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, Mapelli D, Ravdin LD, Romero-Gomez M, Stracciari A, Weissenborn K (2009) Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 29(5):629-635
21. Rivera Ramos JF, Rodriguez Leal C (2011) Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Ann Hepatol 10(Suppl 2):S36-S39
22. Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP (2011) Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther 34(8):853-861
23. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, Als-Nielsen B, Balk EM, Gluud C, Gluud LL, Ioannidis JP, Schulz KF, Beynon R, Welton NJ, Wood L, Moher D, Deeks JJ, Sterne JA (2012) Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 157(6):429-438
24. Sharma BC, Sharma P, Agrawal A, Sarin SK (2009) Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 137(3):885-891, 891.e1. doi: 10.1053/j.gastro.2009.05.056
25. Sharma P, Sharma BC, Agrawal A, Sarin SK (2012) Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 27(8):1329-1335
26. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK (2011) Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 106(2):307-316